Discontinued neuropathic pain therapy between 2009-2015

Expert Opinion on Investigational Drugs

Volumn 24, Issue 12, 2015, Pages 1631-1646

  Knezevic, Nebojsa Nick ^a,b   Cicmil, Nenad ^a   Knezevic, Ivana ^a   Candido, Kenneth D ^a,b  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

discontinued drugs; neuropathic pain; phase I; phase II; phase III

Indexed keywords

3 [3 BROMO 4 (2,4 DIFLUOROBENZYLOXY) 6 METHYL 2 OXO 1(2H) PYRIDINYL] N,4 DIMETHYLBENZAMIDE; ADL 5859; ANALGESIC AGENT; ASP 3652; ATACIGUAT; AZD 1940; AZD 2423; AZD 2516; AZD 6088; BICIFADINE; BVT 115959; GPI 5693; INDANTADOL; NSD 644; PLACULUMAB; Q 8003; RADIPRODIL; SAR 407899; SC 75416; SEP 227900; SEP 228432; SOFINICLINE; UNCLASSIFIED DRUG; NEW DRUG;

CLINICAL RESEARCH; CLINICAL STUDY; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEART ARRHYTHMIA; HUMAN; NEUROPATHIC PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PUBLICATION; QUALITY OF LIFE; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; NEURALGIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; TREATMENT FAILURE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; NEURALGIA; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT FAILURE;

EID: 84949202999     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1099627     Document Type: Review

References (121)

1. van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654-662.
2. Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281-289.
3. BioLineRx. BioLineRx announces publication of EAGLE study results demonstrating BL-1020's efficacy in improving cognitive function in schizophrenia patients [Internet]; 2012. [cited 2015 Jul 30]. Available from: http://www.biolinerx. com/default.asp.pageid=16&itemid=132.
4. BioLineRx. BioLineRx presents pre-clinical data demonstrating that BL-1021 is safe and effective⋯ [Internet]; 2008. [cited 2015 Jul 30]. Available from: http://www.reuters.com/article/2008/01/28/idUS108105+28-Jan-2008 +BW20080128.
5. Nisemblat Y, Savitsky K, Klapper L, et al. BL-1021: new chemical entity for the treatment of neuropathic pain. 13th World Congress on Pain; 2010 Aug 29-Sep 2; Montreal.
6. BioLineRx. BioLineRx announces positive preliminary results from phase I clinical trial of BL-1021 for neuropathic pain [Internet]; 2011. [cited 2015 Jul 30]. Available from: http://www.bioli nerx.com/default.asp?pageid=16&itemid=87.
7. BioLineRx. A study intended to evaluate safety, tolerability and pharmacokinetics (PK) parameters of BL-1021 [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01121380?term=BL-1021&rank=1.
8. Ltd B. BioLineRx announces results from interim analysis of phase II/III CLARITY trial of BL-1020 for schizophrenia [Internet]; 2013. [cited 2015 Jul 30]. Available from: http://www.biolinerx.com/default.asp?pageid=16&itemid=180.
9. Smith SM, Uslaner JM, Hutson PH. The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors. Open Med Chem J. 2010;4:3-9.
10. Sunovion A. Phase 1, open-label, singlephoton emission computed tomography (SPECT) study to evaluate serotonin and dopamine transporter occupancy after multiple dose administration of SEP-228432 to achieve steady state in healthy subjects [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials. gov/ct2/show/record/NCT01531972? term=SEP-228432&rank=1.
11. News RDFD. NSD 644 GlaxoSmithKline discontinued NeuroSearch discontinued NeuroSearch phase change I, Denmark (depression) [Internet]; 2009. [cited 2015 Jul 30]. Available from: http://business.high beam.com/436989/article-1G1-193894086/nsd-644-glaxosmithkline-discontinued-neuro search-discontinued.
12. Guagnini F, Ferazzini M, Grasso M, et al. Erectile properties of the Rhokinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med. 2012;10:59.
13. Grisk OST, Reimer N, Zimmermann U, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012;30(5):980-989.
14. Pharma MGI. Company presentation annual report [Internet]; 2006. [cited 2015 Jul 30]. Available from: http://library.corporate-ir.net/library/73/738/73842/items/240642/MGI06AR.pdf.
15. Peng XQ, Li J, Gardner EL, et al. Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol. 2010;627:1-3.
16. Adinsight [Internet]. 2010. [cited 2015 Jul 30]. Available from: http://adisinsight. springer.com/drugs/800031069.
17. AstraZeneca. Study to investigate the analgesic efficacy of a single dose of AZD1940 [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00659490? term=NCT00659490&rank=1.
18. Neomed. Product pipeline [Internet]; 2015. [cited 2015 Jul 30]. Available from: http://neomed.ca/en/portfolio/.
19. Mattia CCF. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. Idrugs. 2007;10(9):636-644.
20. Vernalis. Study of the safety, tolerability and efficacy of V3381 in patients with diabetic peripheral neuropathic pain [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00794430?term=vernalis&rank=6.
21. Vernalis. Phase II open-label pilot study of V3381 in chronic cough [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01401673?term=vernalis&rank=5.
22. Sanofi. Efficacy and safety study of ataciguat versus placebo in patients with neuropathic pain (SERENEATI) [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00799656?term=ataciguat&rank=2.
23. Sanofi. Efficacy and safety of HMR1766 in patients with fontaine stage II peripheral arterial disease (ACCELA) [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00443287? term=NCT00443287&rank=1.
24. Miller JD. Safety of ataciguat in patients with moderate calcific aortic valve stenosis [Internet]; 2015. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02049203?term=NCT02049203&rank=1.
25. Clinic M. A study evaluating the effects of ataciguat (HMR1766) on aortic valve calcification (CAVS) [Internet]; 2015. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT02481258? term=NCT02481258&rank=1.
26. Zalicus. Phase 2 efficacy trial of Z160 in lumbosacral radiculopathy [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01655849?term=Z-160&rank=1.
27. Zalicus. Efficacy and safety study of Z160 in subjects with postherpetic neuralgia (PHN) [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01757873?term=Z-160&rank=2.
28. Biovitrum SO. Tolerability of novel A2A agonist in treatment of diabetic neuropathic pain [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00452777?term=biovitrum&rank=2.
29. Pharmaceuticals C. Safety and efficacy study of ADL5859 in participants with neuropathic pain associated with diabetic peripheral neuropathy [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clini caltrials.gov/ct2/show/NCT00603265? term=ADL-5859&rank=4.
30. Pharmaceuticals C. Study evaluating the analgesic efficacy and safety of ADL5859 in participants with rheumatoid arthritis [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00626275?term=ADL-5859&rank=1.
31. Pharmaceuticals C. Analgesic efficacy and safety of ADL5859 in subjects with acute dental pain after third molar extraction [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00993863?term=ADL-5859&rank=2.
32. Mony LKJ, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009;157(8):1301-1317.
33. Laboratories F. Study of the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00838799?term=RGH896 &rank=1.
34. Pfizer. PH-797804 LPS study in healthy volunteers [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02084485?term=NCT02084485&rank=1.
35. Pfizer. A study to investigate the effect of PH-797804 on QTc interval [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01862887?term=NCT01862887 &rank=1.
36. Pfizer. A study to investigate the effect of erythromycin on the pharmacokinetics of PH-797804 [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01589614?term=NCT01589614&rank=1.
37. Pfizer. A study to investigate the effect of food on the pharmacokinetics of PH-797804 [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01479647?term=NCT01479647&rank=1.
38. Pfizer. Study to evaluate the efficacy and safety of PH-797804 for 12 weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) on a background of tiotropium bromide [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01543919?term=A6631033&rank=1.
39. Pfizer. Study to evaluate the efficacy and safety of PH-797804 for 12 Weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) taking salmeterol xinafoate/fluticasone propionate combination [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01321463?term=A6631029&rank=1.
40. Pfizer. Clinical trial to examine the pain relief of PH-797804 alone or with naproxen in subjects with osteoarthritis of the knee [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01102660?term=A6631026&rank=1.
41. Pfizer. PH-797804 versus placebo for the treatment of neuropathic pain associated with post-herpetic neuralgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT0061 4705?term=NCT00614705&rank=1.
42. Pfizer. Study to evaluate the efficacy and safety of PH-797804 for 12 weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) on a background of tiotropium bromide [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01543919? term=tiotropium+bromide+PH-797804&rank=1.
43. Pfizer. A phase II, study to evaluate the efficacy and safety of PH-797804 in adults with moderate to severe chronic obstructive pulmonary disease (COPD) [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00559910?term=NCT00559910&rank=1.
44. Pfizer. Clinical trial to examine the pain relief of PH-797804 alone or with naproxen in subjects with osteoarthritis of the knee [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01102660?term=NCT01102660&rank=1.
45. Pfizer. PH-797804 versus placebo for the treatment of neuropathic pain associated with post-herpetic neuralgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00614705?term=NCT00614705 &rank=1.
46. Swedberg MDRP. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J Pharmacol Exp Ther. 2014;350(2):212-222.
47. Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther. 2012;35(10):1231-1242.
48. AstraZeneca. 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01145755.
49. AstraZeneca, editor. Efficacy and safety of the mGluR5 antagonist AZD2066 in painful diabetes neuropathy (PDN): results of a phase IIa randomised, doubleblind, placebo-controlled study [Internet]. 4th World Congress on Pain, 2012 Aug 27-31. [cited 2015 Jul 30]. Available from: http://delta.larvol.com/Products/b352865a0eb941e1a6b7ddaba48cbc0d/AZD2066/8/3185ce22bc0b40089143fc61 66e43534/Efficacy-and-safety-of-themGluR5-antagonist-AZD2066-in-painfuldiabetes-neuropathy-PDN-results-of-aphase-IIa-randomised-doubleblind-placebo controlled-study/.
50. AstraZeneca. To investigate the safety, tolerability and pharmacokinetics of AZD2516 after multiple dosing in healthy volunteers [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01148095.
51. AstraZeneca. An open label positron emission tomography (PET) study to determine central mGluR5 receptor occupancy of AZD2516 [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00892944?term=AZD2516&rank=1.
52. AstraZeneca. Study to assess safety, tolerability and pharmacokinetics after single dose of AZD2516 to Japanese healthy subjects [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00972049?term=AZD2516&rank=2.
53. AstraZeneca. Study to assess safety, tolerability and pharmacokinetics after single doses of AZD2516 to healthy volunteers [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00754715?term=AZD2516&rank=3.
54. AstraZeneca. Study to investigate the pharmacodynamic effect of a single dose of AZD2516 in healthy male subjects [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01154634?term=AZD2516&rank=5.
55. Astellas. R&D Pipeline Q2 [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/2q2015-rd-en.pdf.
56. Astellas. A study to assess the safety, tolerability, and effects in and on the body of healthy young and elderly male and female subjects of ascending multiple oral doses of ASP3652 [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02243657?term=NCT02243657&rank=1.
57. Astellas. A study to assess the pharmacokinetics, metabolism and excretion routes of ASP3652 in man, after administration of 14C radio labeled ASP3652 [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02046798?term=NCT02046798 &rank=1.
58. Astellas. A study to investigate the appearance and disappearance of ASP3652 in blood and spinal fluid in healthy male subjects [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02034734?term=NCT02034734&rank=1.
59. Astellas. A study to assess the effect of race on how a single dose of ASP3652 is taken up, metabolized and distributed through the bodies of young, healthy male and female subjects, and its safety and tolerability [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01958047?term=NCT01958047&rank=1.
60. Astellas. A study to assess the safety, tolerability and effects of single ascending doses of ASP3652 in healthy subjects [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01815684?term=NCT01815684&rank=1.
61. Astellas. A study to assess the effect of multiple doses of gemfribozil on a single dose of ASP3652, and to assess the effects of multiple doses of ASP3652 on a single dose of repaglinide in the body of healthy subjects [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01797198?term=NCT01797198&rank=1.
62. R&D Pipeline [press release] [Internet]. 2013. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/3q2013-rd-en.pdf.
63. Astellas. R&D Pipeline Q1 [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/1q2015-rd-en.pdf.
64. Astellas. R&D Pipeline Q2 [Internet]; 2011. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/2011-rd-en.pdf.
65. Astellas. A clinical study to investigate the efficacy, safety and pharmacokinetics of ASP3652 in patients with chronic abacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) (AZURE) [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01391338?term=ASP-3652&rank=8.
66. Astellas. A randomized study comparing placebo and ASP3652 in the treatment of women with bladder pain syndrome/interstitial cystitis (BPS/IC) (AMARANTH) [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT01613586? term=ASP-3652&rank=7.
67. AbbVie. A safety and efficacy study in subjects with diabetic neuropathic pain; 2007. Available from: https://clinicaltrials.gov/ct2/show/NCT00548925?term=NCT00548925&rank=1.
68. AbbVie. Safety and efficacy study in subjects with diabetic neuropathic pain [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00507936?term=NCT00507936&rank=1.
69. Fleisher CMJ, Mc Gough J. Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attentiondeficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014;23 (8):1157-1163.
70. AbbVie. A dose-ranging study of the efficacy of ABT-894 in adults with attentiondeficit/hyperactivity disorder (ADHD) [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00429091?term=NCT00429091&rank=1.
71. AstraZeneca. Study to investigate safety, tolerability and pharmacokinetics of AZD2423 multiple doses in healthy Japanese volunteers [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01233830?term=NCT01233830 &rank=1.
72. AstraZeneca. Study evaluating absorption, distribution, metabolism and excretion (ADME) of single dose [14C] AZD2423 in volunteers [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01223014?term=NCT01223014&rank=1.
73. AstraZeneca. Study to investigate safety, tolerability and pharmacokinetics of AZD2423 multiple doses in healthy volunteers [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00977626?term=NCT00977626&rank=1.
74. AstraZeneca. AZD2423 single ascending dose study in healthy Japanese subjects (JSAD) [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00970775?term=NCT00970775&rank=1.
75. AstraZeneca. Study to investigate safety, tolerability and pharmacokinetics of AZD2423 in healthy volunteers (SAD) [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials. gov/ct2/show/NCT00940212?term=NCT00940212&rank=1.
76. AstraZeneca. Investigation of the effect of oral treatment with 100 mg AZD2423 in subjects with mild chronic obstructive pulmonary disease (COPD) [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01 153321?term=NCT01153321&rank=1.
77. AstraZeneca. AZD2423 safety and tolerability study in patients with moderate and severe chronic obstructive pulmonary disease(COPD) [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01 215279?term=NCT01215279&rank=1.
78. AstraZeneca. A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials. gov/ct2/show/NCT01200524?term=NCT01200524&rank=1.
79. AstraZeneca. A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01201317?term=NCT01201317&rank=1.
80. Kalliomäki J, Attal N, Jonzon B, et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain. 2013;154(5):761-767.
81. Gierse J, Nickols M, Leahy K, et al. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol. 2008;588 (1):93-98.
82. Obukowicz M, Talley J. Chromene COX-2 inhibitor project [Internet]; 2008. [cited 2015 Jul 30]. Available from: http://eng lish.gibh.cas.cn/drug/ec/cc/.
83. Pfizer. From R&D Focus Drug News [Internet]. 2008 Jan 21. [cited 2015 Jul 30]. Available from: http://business.high beam.com/436989/article-1G1-173550860/sc-75416-pfizer-discontinued.
84. Gay RD, Clarke AW, Elgundi Z, et al. Anti-TNFa domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs. 2010;2(6):625-638.
85. Arana Therapeutics AAHX Trial for Lead Compound [press release] [Internet]. 2008. [cited 2015 Jul 30]. Available from: https://yvepiw.wordpress.com/2012/08/31/arana-announces-phase-ii-trials-forlead-compound-art621/
86. Halloran KJ, Russell BW, Shipplett RA. Patent EP1562900 A1: polymorphs of bicifadine hydrochloride [Internet]; 2006. [cited 2015 Jul 30]. Available from: http://www.google.com.ar/patents/EP1562900A1?cl=en.
87. Nicholson KL, Balster RL, Golembiowska K, et al. Preclinical evaluation of the abuse potential of the analgesic bicifadine. J Pharmacol Exp Ther. 2009;330(1):236-248.
88. Biopharmaceuticals X. A 52-week study of bicifadine in patients with chronic neuropathic pain associated with diabetic peripheral neuropathy [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT00597649? term=bicifadine&rank=4.
89. Pharmaceuticals D. Efficacy and safety of bicifadine in the treatment of chronic low back pain [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00295711?term=bicifa dine&rank=1.
90. Arnold LM, Chatamra K, Hirsch I, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2010;32(9):1618-1632.
91. Pfizer. A trial assessing the effectiveness and safety of [S,S]-reboxetine in patients with fibromyalgia [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT00357825? term=NCT00357825&rank=1.
92. Pfizer. A trial of [S,S]-reboxetine in patients with chronic painful diabetic peripheral neuropathy [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT00625833? term=NCT00625833&rank=1.
93. Pfizer. [S,S]-reboxetine long term safety study in chronic painful diabetic peripheral neuropathy [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT00348894? term=NCT00348894&rank=1.
94. Pfizer. [S,S]-reboxetine add-on trial [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00334685?term=NCT00334685&rank=1.
95. Pfizer. [S,S]-reboxetine long term safety study in post-shingles pain [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT0 0354094?term=NCT00354094&rank=1.
96. Pfizer. A trial assessing the long term safety and tolerability of [S,S]-reboxetine in patients with post-shingles pain [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00353808?term=NCT00353808&rank=1.
97. Pfizer. [S,S]-reboxetine dose-range finding trial [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00288652?term=NCT00288652&rank=1.
98. Pfizer. Study of [S,S]-reboxetine in patients with postherpetic neuralgia, who are gabapentin treatment failures [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00143442?term=NCT00143442&rank=1.
99. Pfizer. Evaluation of a novel methodology in the assessment of urethral function using SS-RBX [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clin icaltrials.gov/ct2/show/NCT00141128? term=NCT00141128&rank=1.
100. Pfizer. An 8 week study looking at the efficacy, toleration and safety of SS-RBX for stress urinary incontinence [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00138749?term=NCT00138749&rank=1.
101. Pfizer. Double-blind, four week trial of [S, S]-reboxetine and atomoxetine in adults with attention deficit hyperactivity disorder [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00562055?term=NCT00562055&rank=1.
102. Pfizer. A 14-week, multi-center study of [S,S]-reboxetine in patients with fibromyalgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00612170?term=NCT00612170&rank=1.
103. Pfizer. Long-term OL study of [S,S]-RBX in patients with fibromyalgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00607256
104. Datamonitor. Pfizer: novel pipeline streamlined post-Wyeth merger [Internet]; 2009. [cited 2015 Jul 30]. Available from: http://www.datamonitor. com/store/News/pfizer-novel-pipeline- streamlined-post-wyeth-merger?produc tid=9DF39DA6-BDBD-4BD5-8620-B848D96166E2.
105. Holaday JW, inventor; Patent WO2012109445 A1-hybrid opioid compounds and compositions [Internet]; 2012. [cited 2015 Jul 30]. Available from: http://www.google.com/patents/WO2012109445A1?cl=en.
106. QRxPharma. Extension study to evaluate the safety of Q8003 in patients with acute moderate to severe pain [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00565760?term=Q8003&rank=6.
107. QRxPharma. Comparison of the efficacy and safety of Q8003 versus its individual components in bunionectomy patients [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00831051?term=Q8003&rank=1.
108. QRxPharma. Pilot study of the efficacy and safety of Q8003 in patients who have undergone total knee arthroplasty or total hip arthroplasty [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00818493?term=Q8003&rank=4.
109. QRxPharma. Comparison of the efficacy and safety of Q8003 versus its individual components in bunionectomy patients [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01016808?term=Q8003&rank=3.
110. QRxPharma. Double blind efficacy and safety study of flexible-dose vs low-dose Q8003 after undergoing primary unilateral total knee arthroplasty [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01055015?term=Q8003&rank=5.
111. QRxPharma. Comparison of the safety of Q8003 versus morphine equivalent doses of its components (oxycodone and morphine) in bunionectomy patients [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01280331?term=Q8003&rank=2.
112. QRxPharma. QRxPharma halts MoxDuo development [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://www.otc markets.com/otciq/ajax/showNewsRelease DocumentById.pdf?id=10835.
113. International Association for the study of pain 2014-2015; Epidemiology of neuropathic pain: how common is neuropathic pain, and what is its impact? [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://iasp.files.cms-plus.com/AM/Images/GYAP/Epidemiology%20of% 20Neuropathic%20Pain.pdf.
114. Lauria G, Faber CG, Merkies ISJ, et al. Diagnosis of neuropathic pain: challenges and possibilities. Expert Opin Med Diagn. 2012;6(2):89-93.
115. Teixeira MJ. Challenges in the treatment of neuropathic pain. Drugs Today (Barc). 2009;45(Suppl C):1-5.
116. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132 (3):237-251.
117. Jongen JL, Hans G, Benzon HT, et al. Neuropathic pain and pharmacological treatment. Pain Pract. 2014;14 (3):283-295.
118. Hoke A, Simpson DM, Freeman R. Designing innovative therapies for neuropathic pain: preclinical and early clinical development challenges. J Peripher Nerv Syst. 2014;19(supplement):S28-S29.
119. Hoke A, Simpson DM, Freeman R. Challenges in developing novel therapies for peripheral neuropathies: a summary of The Foundation for Peripheral Neuropathy Scientific Symposium 2012. J Peripher Nerv Syst. 2013;18(1):1-6.
120. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375 (9715):686-695.
121. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-819.